Recruiting Rheumatoid Arthritis Studies in Columbia
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Coli...
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, a...
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over...
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain t...
About Rheumatoid Arthritis Clinical Trials in Columbia
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 4 rheumatoid arthritis clinical trials recruiting participants in Columbia, MO. These studies are seeking a combined 512 participants. Research is being sponsored by Reistone Biopharma Company Limited, NMD Pharma A/S, Takeda and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in Columbia — FAQ
Are there rheumatoid arthritis clinical trials in Columbia?
Yes, there are 4 rheumatoid arthritis clinical trials currently recruiting in Columbia, MO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Columbia?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbia research site will contact you about next steps.
Are clinical trials in Columbia free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Columbia studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 4 active trials in Columbia are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated March 2, 2026 from ClinicalTrials.gov